[go: up one dir, main page]

ES2069345T3 - HETERO-CYCLICAL ANALOGS OF AMIDA-PROSTAGLANDINA 7-OXABICICLO-HEPTIL-SUBSTITUTES USEFUL IN THE TREATMENT OF THROMBOTIC AND VASO-SPASTIC DISEASES. - Google Patents

HETERO-CYCLICAL ANALOGS OF AMIDA-PROSTAGLANDINA 7-OXABICICLO-HEPTIL-SUBSTITUTES USEFUL IN THE TREATMENT OF THROMBOTIC AND VASO-SPASTIC DISEASES.

Info

Publication number
ES2069345T3
ES2069345T3 ES92108848T ES92108848T ES2069345T3 ES 2069345 T3 ES2069345 T3 ES 2069345T3 ES 92108848 T ES92108848 T ES 92108848T ES 92108848 T ES92108848 T ES 92108848T ES 2069345 T3 ES2069345 T3 ES 2069345T3
Authority
ES
Spain
Prior art keywords
analogs
oxabiciclo
heptil
prostaglandina
amida
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92108848T
Other languages
Spanish (es)
Inventor
Steven E Hall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of ES2069345T3 publication Critical patent/ES2069345T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

7-Oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs are provided which are thromboxane A2 (TXA2) receptor antagonists or combined thromboxane A2 receptor antagonist/thromboxane synthetase inhibitors and have the structural formula <CHEM> wherein R is SO3H, P(O)OR<3>OH or P(O)R<4>OH, X is O or NH, and Z, R<1>, R<2>, R<3> and R<4> are as defined herein.
ES92108848T 1991-06-12 1992-05-26 HETERO-CYCLICAL ANALOGS OF AMIDA-PROSTAGLANDINA 7-OXABICICLO-HEPTIL-SUBSTITUTES USEFUL IN THE TREATMENT OF THROMBOTIC AND VASO-SPASTIC DISEASES. Expired - Lifetime ES2069345T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/713,898 US5158967A (en) 1991-06-12 1991-06-12 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease

Publications (1)

Publication Number Publication Date
ES2069345T3 true ES2069345T3 (en) 1995-05-01

Family

ID=24867989

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92108848T Expired - Lifetime ES2069345T3 (en) 1991-06-12 1992-05-26 HETERO-CYCLICAL ANALOGS OF AMIDA-PROSTAGLANDINA 7-OXABICICLO-HEPTIL-SUBSTITUTES USEFUL IN THE TREATMENT OF THROMBOTIC AND VASO-SPASTIC DISEASES.

Country Status (8)

Country Link
US (1) US5158967A (en)
EP (1) EP0518118B1 (en)
JP (1) JPH05194524A (en)
AT (1) ATE119532T1 (en)
CA (1) CA2070895A1 (en)
DE (1) DE69201596T2 (en)
DK (1) DK0518118T3 (en)
ES (1) ES2069345T3 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260448A (en) * 1992-03-06 1993-11-09 E. R. Squibb & Sons, Inc. Method for preparing 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5347007A (en) * 1992-03-06 1994-09-13 E. R. Squibb & Sons, Inc. Method of preparing 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5260449A (en) * 1992-08-12 1993-11-09 E. R. Squibb & Sons, Inc. Method for preparing 7-oxabicycloheptyl substituted bromooxazole amide prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds
US5496849A (en) * 1992-09-18 1996-03-05 Toray Industries, Inc. Sulfonic acid derivative and its pharmaceutical application
EP0662834A4 (en) * 1992-09-22 1996-04-17 Cell Therapeutics Inc Novel epoxide-containing compounds.
US5866576A (en) * 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
US5849766A (en) * 1996-05-31 1998-12-15 Eli Lilly And Company Carbamoyl substituted heterocycles
US5849922A (en) * 1996-05-31 1998-12-15 Eli Lilly And Company Preparation of substituted alkenoic acids
WO2009089098A1 (en) 2008-01-03 2009-07-16 Musc Foundation For Research Development Methods for the treatment of cancers
CN117122687A (en) 2017-11-29 2023-11-28 凡德贝尔大学 Methods for inhibiting tumor metastasis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922301A (en) * 1973-06-19 1975-11-25 Ono Pharmaceutical Co Sulphonic acid derivatives of prostaglandins
US4418076A (en) * 1982-05-03 1983-11-29 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane hydrazone prostaglandin analogs useful in treating thrombolytic diseases
US4556675A (en) * 1982-05-17 1985-12-03 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane and 7-oxabicycloheptene compounds
US4416896A (en) * 1982-05-17 1983-11-22 E. R. Squibb & Sons, Inc. 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease
US4463015A (en) * 1982-08-18 1984-07-31 E. R. Squibb & Sons, Inc. Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation
US4474804A (en) * 1983-09-19 1984-10-02 E. R. Squibb & Sons, Inc. 7-Oxabicyclo substituted prostaglandin phenyl carboxylic acid derivatives useful as cardiovascular agents
US4522949A (en) * 1983-10-20 1985-06-11 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane substituted prostaglandin interphenylene analogs useful as cardiovascular agents
US4536513A (en) * 1984-03-14 1985-08-20 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane substituted prostaglandin interphenylene analogs useful in the treatment of thrombolytic disease
US4663336A (en) * 1985-07-01 1987-05-05 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease
US4663337A (en) * 1986-04-18 1987-05-05 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted amides useful in the treatment of thrombotic disease
ZA899868B (en) * 1988-12-23 1990-09-26 Squibb & Sons Inc 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
NZ232897A (en) * 1989-04-03 1992-12-23 Squibb & Sons Inc Interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogues, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
DE69201596T2 (en) 1995-09-07
JPH05194524A (en) 1993-08-03
EP0518118B1 (en) 1995-03-08
ATE119532T1 (en) 1995-03-15
DK0518118T3 (en) 1995-05-22
EP0518118A1 (en) 1992-12-16
US5158967A (en) 1992-10-27
DE69201596D1 (en) 1995-04-13
CA2070895A1 (en) 1992-12-13

Similar Documents

Publication Publication Date Title
DK0675886T3 (en) Aminomethylene-substituted non-aromatic heterocycles and their use as substance P antagonists
IS6275A (en) Heterocyclic compounds and their use as antagonists of metabolic glutamate receptors
NO178969C (en) Analogous process for the preparation of therapeutically active substituted quinazolinones
DK260588D0 (en) HETEROCYCLIC KETONS
ES2167720T3 (en) 1-PHENYLPIRAZOL COMPOUNDS AND MEDICINAL APPLICATIONS OF THE SAME.
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
EA200300982A1 (en) HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES
ES2069345T3 (en) HETERO-CYCLICAL ANALOGS OF AMIDA-PROSTAGLANDINA 7-OXABICICLO-HEPTIL-SUBSTITUTES USEFUL IN THE TREATMENT OF THROMBOTIC AND VASO-SPASTIC DISEASES.
UA41904C2 (en) METHOD OF OBTAINING BENZOPYRANE COMPOUNDS, INTERMEDIATES, METHOD OF OBTAINING INTERMEDIATE COMPOUNDS
ATE272617T1 (en) SULFONAMIDE DERIVATIVES
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
NO20000737D0 (en) Tetrahydro &lt;gamma&gt; carbolines
DK0453960T3 (en) Sulfonylamino-substituted bicyclic hydroxamic acid derivatives
DE69329184D1 (en) Alkyl substituted heterocyclic compounds
ES2132245T3 (en) DERIVATIVES OF 1-AZAADAMANTHANE AS 5-HT AGONISTS OR ANTAGONISTS.
DK0630893T3 (en) N, N&#39;-disubstituted amide derivative
FI883134A0 (en) FLUORHALTIGA RENIN INHIBITOR.
ATE275558T1 (en) 4-ARYLPIPERIDINE DERIVATIVES FOR THE TREATMENT OF PRURITUS
DE69527854D1 (en) DERIVATE SUBSTITUTED AMIDINONAPHTHYLESTER
ATE145911T1 (en) INOSITOL PHOSPHATE ANALOG AS A CALCIUM ANTAGONIST SUBSTANCE
DK0428132T3 (en) Pradimicin derivatives
ATE114309T1 (en) N-AZABICYCLO(3.3.0&gt;OCTANAMIDES OF AROMATIC ACIDS.
TH51662A (en) Vitronectin receptor antagonist

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 518118

Country of ref document: ES